CooperVision has announced it has completed enrolment of its global MiSight 1 day post-approval clinical studies in the US and China.
CooperVision said this milestone in real-world evidence generation for paediatric myopia control, together with the seven-year clinical trial of ActivControl Technology, represents the longest clinical evidence programme undertaken for contact lens-based myopia control intervention in children.
The post-approval studies comprise both randomised controlled efficacy trials and large-scale safety registries and include 100-plus clinical sites and more than 3,000 children. Data will supplement the MiSight 1 day clinical studies, which have been widely published and cited in the ophthalmology and optometry communities, the company said.
